Gemina Laboratories Ltd. (GLABF)
USD 0.44
(-2.91%)
USD 0.44
(-2.91%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 285.32 Thousand CAD | 101.51% |
| 2023 | 240.84 Thousand CAD | 422.68% |
| 2022 | 46.07 Thousand CAD | -53.04% |
| 2021 | 98.12 Thousand CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q4 | 285.32 Thousand CAD | -43.31% |
| 2024 FY | 285.32 Thousand CAD | 18.47% |
| 2024 Q2 | 321.3 Thousand CAD | 39.31% |
| 2024 Q3 | 503.28 Thousand CAD | 56.64% |
| 2024 Q1 | 230.64 Thousand CAD | -4.24% |
| 2023 Q3 | 250.76 Thousand CAD | 1911.59% |
| 2023 Q2 | 12.46 Thousand CAD | -57.66% |
| 2023 Q1 | 29.44 Thousand CAD | -36.11% |
| 2023 FY | 240.84 Thousand CAD | 422.68% |
| 2023 Q4 | 240.84 Thousand CAD | -3.96% |
| 2022 Q2 | 68.46 Thousand CAD | -17.95% |
| 2022 Q1 | 83.44 Thousand CAD | 121.92% |
| 2022 FY | 46.07 Thousand CAD | -53.04% |
| 2022 Q4 | 46.07 Thousand CAD | -13.37% |
| 2022 Q3 | 53.18 Thousand CAD | -22.32% |
| 2021 Q4 | 37.6 Thousand CAD | 0.0% |
| 2021 FY | 98.12 Thousand CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 99.308% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 93.078% |
| SQZ Biotechnologies Company | 27.47 Million USD | 98.961% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 99.342% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 99.041% |
| Mesoblast Limited | 118.7 Million USD | 99.76% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 69.911% |
| Genus plc | 233.1 Million USD | 99.878% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 90.263% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 78.764% |
| Marizyme, Inc. | 18.71 Million USD | 98.476% |
| ContraFect Corporation | 2.88 Million USD | 90.096% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 61.957% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -110.593% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 80.272% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 87.733% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 94.957% |
| MultiCell Technologies, Inc. | 202.58 USD | -140746.085% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 99.504% |
| EV Biologics, Inc. | 1.49 Million USD | 80.911% |
| Q BioMed Inc. | 4.1 Million USD | 93.058% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 99.138% |
| Neon Bloom, Inc. | 630.07 Thousand USD | 54.716% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 76.772% |
| Biomind Labs Inc. | 735.54 Thousand USD | 61.209% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.834% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 97.805% |
| Skye Bioscience, Inc. | 4.61 Million USD | 93.818% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 67.871% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -101.618% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 95.14% |
| IMV Inc. | 28.88 Million USD | 99.012% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -1009.398% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 87.366% |
| GB Sciences, Inc. | 1.75 Million USD | 83.782% |
| Alpha Cognition Inc. | 1.22 Million USD | 76.62% |
| HST Global, Inc. | 98.31 Thousand USD | -190.204% |
| CSL Limited | 12.18 Billion USD | 99.998% |
| Halberd Corporation | 150 Thousand USD | -90.217% |
| Enzolytics Inc. | 996.33 Thousand USD | 71.363% |
| Resverlogix Corp. | 6.49 Million USD | 95.604% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | 40.246% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -11.633% |
| argenx SE | 20 Million USD | 98.573% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 99.374% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 89.466% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -2690.474% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.932% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -42.225% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 88.1% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -24.438% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.578% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 90.571% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 20.679% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 98.596% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -91.94% |
| BioStem Technologies, Inc. | 4.71 Million USD | 93.944% |
| ONE Bio Corp. | 19.71 Million USD | 98.553% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -14.047% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -14.718% |
| Agentix Corp. | 50 Thousand USD | -470.652% |
| LadRx Corporation | 33.6 Thousand USD | -749.033% |
| Cell Source, Inc. | 9.25 Million USD | 96.917% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 62.269% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 62.269% |
| NovAccess Global Inc. | 2.19 Million USD | 87.03% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 95.966% |
| Itoco Inc. | 228.37 Thousand USD | -24.936% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -35.242% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 94.274% |
| Kadimastem Ltd | 891.22 Thousand USD | 67.985% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 28.997% |
| CytoDyn Inc. | 30.07 Million USD | 99.051% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | 41.083% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | 18.906% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 96.351% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -132.919% |
| Rebus Holdings, Inc. | 310 Thousand USD | 7.959% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 93.974% |
| International Stem Cell Corporation | 4.17 Million USD | 93.171% |
| Bioxytran, Inc. | 1.92 Million USD | 85.178% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -357.158% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 86.917% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 96.569% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 96.676% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 81.657% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -6.465% |
| Neutra Corp. | 54.15 Thousand USD | -426.859% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 84.408% |
| PureTech Health plc | 25.51 Million USD | 98.882% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 76.693% |
| IXICO plc | 472.02 Thousand USD | 39.553% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 98.159% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 99.542% |
| CSL Limited | 12.18 Billion USD | 99.998% |
| Cellectis S.A. | 92.77 Million USD | 99.692% |